Vol. 19/No. 24 | OncologyLive

Advanced Gastroesophageal Cancer: What Have We Learned, and What's Next

December 29, 2018

Investigators have achieved some success with immune checkpoint inhibitors and antiangiogenesis agents in patients with advanced gastroesophageal cancers, and exciting new agents targeting different tumor growth pathways are under investigation.

Targeting Cancer's Achilles Heel: DNA Damage Response Networks Beyond PARP

December 27, 2018

Cancer cells must maintain a delicate balance to prevent catastrophic levels of DNA damage from triggering cell death, and their heavy reliance on the remaining normal DNA damage response components creates a therapeutically targetable Achilles’ heel.

UVA Screening Program Seeks to Get Ahead of Colorectal Cancer

December 26, 2018

Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.

Biomarker Hunt Focuses on Predicting Immunotherapy Adverse Events

December 26, 2018

Although the need for biomarkers of immunotherapy response has generated much attention, investigators also are pursuing mechanisms for distinguishing which patients will experience adverse effects from these therapies.

Developing Alternative Payment Models That Providers and Commercial Payers Support

December 24, 2018

Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.

Tucatinib Shows Promise in Patients With Breast Cancer and Brain Metastases

December 21, 2018

Evidence continues to build that tucatinib, a novel small molecule HER2 inhibitor, is safe and effective for patients with advanced HER2-positive breast cancer in combination with standard therapies, including for those who develop brain metastases.